- Activity pressure is positive on the latest completed week.
CBHD
GER
Week ended 24 Jul 2026
Weekly Investor Report
Coloplast A/S · Healthcare · Medical Instruments & Supplies
Latest close
54.30 EUR
-4.1%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is -2.4% below the Trend Line and sits at 31.1% of its 52-week range. The latest completed week returned -4.1%, after a 6.4% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is inexpensive relative to peers. The latest news-sentiment score is 58/100. Near-term considerations: volume confirmation is below normal.
Setup score
44
out of 100
Latest Close
54.30 EUR
24 Jul 2026
1W Return
-4.1%
latest completed week
4W Return
6.4%
short-term follow-through
12W Return
14.1%
quarterly tape
Trend Breadth
21.2%
11 of 52 weeks active
Volume Ratio
0.7x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is weak, so confirmation is not yet broad enough.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-4.1%
Latest completed week; four-week move 6.4%.
Indicator stack
12/100
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
58/100
6 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -2.4% below the Trend Line and sits at 31.1% of its 52-week range. The latest completed week returned -4.1%, after a 6.4% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.7x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
30 Jan
6 Feb
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.1112-week average 0.07
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure4/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.11Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 6.4% over four weeks, 14.1% over 12 weeks, and -6.9% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year11
Trend breadth21.2%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.83Latest activity-pressure read.
Pressure change3487.2%Four-week change in activity pressure.
Leadership-7.26Latest relative-leadership reading.
RS change39.1%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is inexpensive relative to peers.
Factor week 26 Jul 2026
Financial statements through 30 Sep 2024
Field coverage 94%
Model confidence 90%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength96/100Blend of value, momentum, and quality. Underlying universe rank 5; rank 1 is best.
Value99/100Relative valuation strength. Underlying universe rank 2; rank 1 is best.
Quality93/100Profitability and accounting quality. Underlying universe rank 8; rank 1 is best.
Momentum28/100Medium-term price momentum. Underlying universe rank 73; rank 1 is best.
Growth75/100Revenue and earnings growth. Underlying universe rank 26; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework99/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 5.7x Price divided by trailing earnings.
- Price / sales
- 0.4x Market value relative to trailing revenue.
- EV / EBITDA
- 4.0x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 12.7% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 67.4% Gross profit retained from each unit of revenue.
- Operating margin
- 26.7% Operating profit retained from revenue.
- Free-cash-flow margin
- 16.0% Free cash flow generated from revenue.
- Return on invested capital
- 15.6% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 10.3% Latest one-year revenue growth.
- EPS growth
- 5.3% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- -52.4% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 6/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 5.7% Cash dividends relative to market value.
- Buyback yield
- -4.1% Net share repurchases relative to market value.
- Shareholder yield
- 1.6% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 2.6x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment58/100
Weighted news tone is neutral across 6 relevant articles.
2 positive · 4 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-22.9%Distance below the 52-week high.
13-week volatility4.6%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
30 Jan
27 Feb
27 Mar
24 Apr
22 May
19 Jun
24 Jul
Weeks higher10 of 2616 weeks finished lower.
Best week+12.2%Week of 22 May.
Worst week-7.4%Week of 6 Feb.
Latest week-4.1%Week of 24 Jul.
Shape of recent returns
Strong gains3
Modest gains7
Flat weeks0
Modest losses10
Sharp losses6
Recent vol4.6%13-week weekly-return volatility.
Base vol5.5%52-week weekly-return volatility.
Up/down split22/30Count of positive and negative weeks in the 52-week window.
Average skew4.5% / -3.3%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorDE Healthcare
4-week rank18 / 78
Group average1.5%
Trend breadth38.5%
Trend38.5%active weekly trend signals
MD64.1%positive activity pressure
RS43.6%positive relative leadership
Four-week leaders
IndustryDE Medical Instruments & Supplies
4-week rank3 / 12
Group average-0.6%
Trend breadth16.7%
Trend16.7%active weekly trend signals
MD66.7%positive activity pressure
RS8.3%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape39/100
Trend, activity pressure, participation, and risk combine to a 39/100 tape read.
Indicator analysis17/100Latest 12-week confirmation: trend 0/12, activity pressure 4/12, relative leadership 0/12.
Activity pressure 0.11; No reversal markers Factors80/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 96; Small Cap Core rank 7 SVQF99/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 5.5 of 373 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment58/100Weighted news tone is neutral across 6 relevant articles.
Coloplast A/S Class B Revenue Breakdown – HAM:CBHD Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 24 Jul 2026 | 54.30 EUR | -4.1% | 55.64 EUR | 59.73 EUR | 0.83 | -7.26 | 4.7K | Off |
| 17 Jul 2026 | 56.62 EUR | 5.2% | 56.03 EUR | 59.71 EUR | 0.86 | -2.45 | 10.1K | Off |
| 10 Jul 2026 | 53.82 EUR | 1.9% | 56.35 EUR | 59.67 EUR | 0.53 | -8.19 | 12.3K | Off |
| 3 Jul 2026 | 52.84 EUR | 3.6% | 56.83 EUR | 59.64 EUR | 0.25 | -12.48 | 10.0K | Off |
| 26 Jun 2026 | 51.02 EUR | 2.4% | 57.42 EUR | 59.62 EUR | -0.02 | -11.93 | 9.6K | Off |
| 19 Jun 2026 | 49.82 EUR | -2.4% | 57.56 EUR | 59.63 EUR | -0.16 | -15.28 | 1.3K | Off |
| 12 Jun 2026 | 51.04 EUR | -1.4% | 57.71 EUR | 59.64 EUR | -0.15 | -12.31 | 1.6K | Off |
| 5 Jun 2026 | 51.74 EUR | -2.0% | 57.88 EUR | 59.66 EUR | -0.32 | -11.91 | 1.6K | Off |
| 29 May 2026 | 52.82 EUR | -2.0% | 58.04 EUR | 59.66 EUR | -0.56 | -11.55 | 7.9K | Off |
| 22 May 2026 | 53.92 EUR | 12.2% | 58.10 EUR | 59.67 EUR | -0.88 | -9.21 | 6.2K | Off |
| 15 May 2026 | 48.06 EUR | -2.5% | 58.22 EUR | 59.67 EUR | -1.02 | -16.13 | 10.1K | Off |
| 8 May 2026 | 49.31 EUR | 3.6% | 58.44 EUR | 59.72 EUR | -1.00 | -15.70 | 4.9K | Off |
| 1 May 2026 | 47.61 EUR | -5.4% | 58.54 EUR | 59.75 EUR | -0.89 | -18.82 | 6.1K | Off |
| 24 Apr 2026 | 50.34 EUR | -7.2% | 58.74 EUR | 59.82 EUR | -0.85 | -14.06 | 10.5K | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.